- Home
- PHAR vs IGIC Comparison
PHAR vs IGIC Comparison
Compare PHAR & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | IGIC |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | Netherlands | Jordan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHAR | IGIC |
|---|---|---|
| Price | $17.10 | $25.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $38.00 | $30.33 |
| AVG Volume (30 Days) | 32.4K | ★ 46.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.75 | $34.82 |
| Revenue Next Year | $9.39 | $4.01 |
| P/E Ratio | $3,041.22 | ★ $9.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.50 | $20.82 |
| 52 Week High | $21.34 | $27.63 |
Technical Indicators
Market Signals| Indicator | PHAR | IGIC |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 51.36 |
| Support Level | $16.35 | $22.68 |
| Resistance Level | $17.08 | $25.54 |
| Average True Range (ATR) | 0.57 | 0.75 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 77.74 | 26.04 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.